PMA device
Amplatzer Amulet LAA Occluder
Abbott Medical · System, Appendage Closure, Left Atrial (NGV, Class III) · First FDA decision Dec 9, 2021, newest Dec 9, 2021Stroke prevention in atrial fibrillation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
6
Naming "Amplatzer Amulet LAA"
MAUDE reports
2
Brand "Amplatzer Amulet LAA", since 2015
PubMed studies
15
Mentioning "Amplatzer Amulet LAA"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Amplatzer Amulet LAA Occluder
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Amplatzer Amulet LAA OccluderPMA supplement
P200049-S002 · Decided Dec 9, 2021 · 87 days after receipt · Normal 180 Day Track No User Fee
Device type: System, appendage closure, left atrial (NGV) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Left Atrial Appendage Closure (LAAC)National determinationOn the books20.34Updated Nov 4, 2026
- Percutaneous Left Atrial Appendage (LAA) Closure TherapyNational analysisReview closedCAG-00445NUpdated Sep 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Amplatzer Amulet LAA", any status and sponsor, newest update first.
Abbott Medical DevicesPublic (ABT)
NCT06189365 · 50 participants · Start Jan 30, 2024 · Primary completion Dec 5, 2025
Device: Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder · For: Non-Valvular Atrial Fibrillation
Sites: Shenzhen, China; Wuhan, China; Changsha, China · 5 sites in all
- 3D Printing Technology For Planning Left Atrial Appendage OcclusionPivotal-lookingCompleted
Chinese University of Hong KongAcademic, hospital or other
NCT07483008 · 184 participants · Start Oct 1, 2017 · Primary completion Jan 31, 2022
Device: 3D-printed models of the left atrial appendage · For: Atrial Fibrillation (AF); 3D Printing; Cost Benefit Analysis
Sites: Hong Kong, Hong Kong
- Amplatzer Amulet LAAO vs. NOACPivotal-lookingActive, not recruiting
Abbott Medical DevicesPublic (ABT)
NCT04226547 · 2,650 participants (planned) · Start Jul 7, 2020 · Primary completion Jan 2029
Device: Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder) · For: Atrial Fibrillation; Stroke; Bleeding
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 127 sites in all
3 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Amplatzer Amulet LAA", and for the whole product code for context.
This brand
2 reports: 0 malfunction, 2 injury, 0 death
Whole product code NGV
17,771 reports: 1,912 malfunction, 13,990 injury, 1,862 death
Newest reports for this brand
MW5144779 · Received Aug 18, 2023 · Event dated Aug 3, 2023
Device type: Occluder, Patent Ductus, Arteriosus (MAE)
Patient problem as coded: Perforation
MW5112633 · Received Oct 13, 2022 · Event dated Oct 7, 2022
Device type: Transcatheter Septal Occluder (MLV)
Device problem as coded: Migration or Expulsion of Device
Patient problem as coded: Insufficient Information
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0191-2027 · Started Sep 10, 2026 · Posted by FDA Oct 16, 2026
Reason given: Changes to Instructions for Use (IFU) for the device regarding risk of Pulmonary Artery Injury (PAI).
Cause as FDA categorized it: Labeling design · Device type: System, Appendage Closure, Left Atrial (NGV)
Published research
The most relevant PubMed records for "Amplatzer Amulet LAA"[tiab]. The summary above synthesizes these.
- 3-Year Outcomes From the Amplatzer Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE).
Lakkireddy D, Thaler D, Ellis CR, et al. · JACC Cardiovasc Interv · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Left Atrial Appendage Occlusion for Stroke Prevention.
Chanda A, Reilly JP · Prog Cardiovasc Dis · 2017Review
- Device-Related Thrombus Formation With the Amplatzer Amulet LAA Device: Optimal Implantation = Optimal Results.
Sawaya FJ, Chow DHF, Millan-Iturbe O, et al. · JACC Clin Electrophysiol · 2017Letter, Comment
- First Experience With Amulet in the United States: Early Insights From EMERGE LAA Postapproval Study.
Alkhouli M, Freeman JV, Ellis CR, et al. · JACC Cardiovasc Interv · 2024
- Mechanisms, predictors, and evolution of severe peri-device leaks with two different left atrial appendage occluders.
Lakkireddy D, Nielsen-Kudsk JE, Windecker S, et al. · Europace · 2023Randomized Controlled Trial
- Safety of Amulet Left Atrial Appendage Occluder and Watchman Device for Left Atrial Appendage Closure in Patients With Atrial Fibrillation.
Sawaya F, Abi-Saleh B, Hoteit A, et al. · Cureus · 2024
- Rationale and design of a global registry to evaluate real-world clinical outcomes in patients with atrial fibrillation and high risk of stroke treated with left atrial appendage occlusion using the AMPLATZER amulet device-Perspective of available/ongoing registries of catheter-based LAA occlusion.
Hildick-Smith D, Diener HC, Schmidt B, et al. · Catheter Cardiovasc Interv · 2018Multicenter Study, Observational Study
- Reply: Device-Related Thrombus Formation With the Amplatzer Amulet LAA Device: Optimal Implantation = Optimal Results.
Sedaghat A, Hammerstingl C · JACC Clin Electrophysiol · 2017Letter, Comment
- Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry.
Landmesser U, Tondo C, Camm J, et al. · EuroIntervention · 2018Observational Study
- Sex Differences in Safety and Effectiveness of LAAO: Insights From the Amulet IDE Trial.
Alkhouli M, Russo AM, Thaler D, et al. · JACC Cardiovasc Interv · 2022Clinical Trial, Research Support, Non-U.S. Gov't
- Incidence, Predictors, and Clinical Outcomes of Device-Related Thrombus in the Amulet IDE Trial.
Schmidt B, Nielsen-Kudsk JE, Ellis CR, et al. · JACC Clin Electrophysiol · 2023Clinical Trial, Research Support, Non-U.S. Gov't
- Amplatzer Amulet left atrial appendage occluder entrapment through mitral valve.
González-Santos JM, Arnáiz-García ME, Arribas-Jiménez A, et al. · Can J Cardiol · 2013Case Reports
Other devices of this type
Also filed under product code NGV.
- Watchman Left Atrial Appendage (Laa) Closure TechnologyBoston Scientific Corp · PMA 2026
- WATCHMAN FLX Left Atrial Appendage (LAA) Closure TechnologyBoston Scientific Corp · PMA 2025
- WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery SystemBoston Scientific Corp · PMA 2025
- Amplatzer Amulet Left Atrial Appendage OccluderAbbott Medical · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.